For research use only. Not for therapeutic Use.
IRF5-IN-1 (compound C5) is an IRF5 pathway-specific inhibitor. IRF5-IN-1 significantly reduces IRF5 nuclear translocation without affecting the activation of NF-κB p65. IRF5-IN-1 acts through SLC15A4 to selectively inhibit TLR7/8-induced IRF5 responses in cells[1].
| Catalog Number | I040608 |
| CAS Number | 689270-18-6 |
| Synonyms | 2-(4-ethoxyphenyl)-N-[3-(2-methylpiperidin-1-yl)propyl]quinoline-4-carboxamide |
| Molecular Formula | C27H33N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H33N3O2/c1-3-32-22-14-12-21(13-15-22)26-19-24(23-10-4-5-11-25(23)29-26)27(31)28-16-8-18-30-17-7-6-9-20(30)2/h4-5,10-15,19-20H,3,6-9,16-18H2,1-2H3,(H,28,31) |
| InChIKey | CJAGKBRBMHETMY-UHFFFAOYSA-N |
| SMILES | CCOC1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)NCCCN4CCCCC4C |
| Reference | [1]. Andras Boeszoermenyi, et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat Commun. 2023 Oct 20;14(1):6626. |
